Maryam Nakhjavani

Dr. Maryam Nakhjavani

Blood Cancer Drivers & Therapeutics Laboratory, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Australia
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2017 in Heat and Mass Transfer
Verified
Journal Article
Closed access
PDF file
Maryam NakhjavaniMaryam Nakhjavani
Maryam Nakhjavani
VNV. Nikkhah
V. Nikkhah
SSSaeed Shoja
Saeed Shoja
MSMarzieh Sarafraz
Marzieh Sarafraz

23 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Maryam NakhjavaniMaryam Nakhjavani
Maryam Nakhjavani
ESEric Smith
Eric Smith
ATAmanda R. Townsend
Amanda R. Townsend
TPTimothy J Price
Timothy J Price
JHJenny Hardingham
Jenny Hardingham
Ginsenoside Rg3 (Rg3) is a member of the ginsenoside family of chemicals extracted from Panax ginseng. Like other ginsenosides, Rg3 has two epimers: 20(S)-ginsenoside Rg3 (SRg3) and 20(R)-ginsenoside Rg3 (RRg3). Rg3 is an intriguing molecule due to its anti-cancer properties. One facet of the anti-cancer properties of Rg3 is the anti-angiogenic action. This review describes the controversies on the effects and effective dose range of Rg3, summarizes the evidence on the efficacy of Rg3 on angiogenesis, and raises the possibility that Rg3 is a prodrug.

23 January 2019 in Medicines
Verified
Journal Article
Open access
PDF file
Maryam NakhjavaniMaryam Nakhjavani
Maryam Nakhjavani
JHJenny Hardingham
Jenny Hardingham
HPHelen Palethorpe
Helen Palethorpe
YTYoko Tomita
Yoko Tomita
ESEric Smith
Eric Smith
ATAmanda R Townsend
Amanda R Townsend
Breast cancer is still one of the most prevalent cancers and a leading cause of cancer death worldwide. The key challenge with cancer treatment is the choice of the best therapeutic agents with the least possible toxicities on the patient. Recently, attention has been drawn to herbal compounds, in particular ginsenosides, extracted from the root of the Ginseng plant. In various studies, significant anti-cancer properties of ginsenosides have been reported in different cancers. The mode of action of ginsenoside Rg3 (Rg3) in in vitro and in vivo breast cancer models and its value as an anti-cancer treatment for breast cancer will be reviewed.

1 August 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Maryam NakhjavaniMaryam Nakhjavani
Maryam Nakhjavani
HPHelen Palethorpe
Helen Palethorpe
YTYoko Tomita
Yoko Tomita
ESEric Smith
Eric Smith
TPTimothy J Price
Timothy J Price
JHJenny Hardingham
Jenny Hardingham
Ginsenoside Rg3 (Rg3) has two epimers, 20(S)-ginsenoside Rg3 (SRg3) and 20(R)-ginsenoside Rg3 (RRg3), and while Rg3 itself has been reported to have anti-cancer properties, few studies have been reported on the anti-cancer effects of the different epimers. The aim was to investigate the stereoselective effects of the Rg3 epimers on triple negative breast cancer (TNBC) cell lines, tested using cell-based assays for proliferation, apoptosis, cell cycle arrest, migration and invasion. Molecular docking showed that Rg3 interacted with the aquaporin 1 (AQP1) water channel (binding score −9.4 kJ mol−1). The Xenopus laevis oocyte expression system was used to study the effect of Rg3 epimers on the AQP1 water permeability. The AQP1 expression in TNBC cell lines was compared with quantitative-polymerase chain reaction (PCR). The results showed that only SRg3 inhibited the AQP1 water flux and inhibited the proliferation of MDA-MB-231 (100 μM), due to cell cycle arrest at G0/G1. SRg3 inhibited the chemoattractant-induced migration of MDA-MB-231. The AQP1 expression in MDA-MB-231 was higher than in HCC1143 or DU4475 cell lines. These results suggest a role for AQP1 in the proliferation and chemoattractant-induced migration of this cell line. Compared to SRg3, RRg3 had more potency and efficacy, inhibiting the migration and invasion of MDA-MB-231. Rg3 has stereoselective anti-cancer effects in the AQP1 high-expressing cell line MDA-MB-231.

1 January 2019 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
Maryam NakhjavaniMaryam Nakhjavani
Maryam Nakhjavani
JHJenny Hardingham
Jenny Hardingham
HPHelen Palethorpe
Helen Palethorpe
TPTim J Price
Tim J Price
ATAmanda R Townsend
Amanda R Townsend
Nakhjavani M, et al. J Breast Cancer. 2019 Jul;22:e39. https://doi.org/10.4048/jbc.2019.22.e39

1 January 2022 in Pharmacological Research
Verified
Journal Article
Closed access
Maryam NakhjavaniMaryam Nakhjavani
Maryam Nakhjavani
SSSarah Shigdar
Sarah Shigdar